|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Diagnosis**  | **Pictilisib QD Dose** | **Time on Study (months)** | **Day 15 AUC (hr.uM)** | **Best RECIST Response** | **Best FDG-PET Response** | **pS6 Change** | **pAKT Change** | **CA-125 Change** |  **Pathway Alteration** |
| GIST | 450 mg | 7.4 | 22.9 | -1.5% | -47% | -75% | ND | - | None |
| Cervix cancer | 340 mg | 3.3 | 25.2 | 1.7% | -31% | ND | ND | - | None |
| Melanoma  | 330 mg | 9.5 | 15.4 | -39.2% PR | 5% | ND | -73% | - | BRAF V600E |
| Colorectal cancer | 330 mg | 3.7 | 32.4 | 11.9% | -46% | ND | -97% | - | KRAS G12C, PTEN decreased |
| GIST | 330 mg  | 2.1 | 31.0 | 10.4% | -37% | ND | -100% | - | None |
| Colorectal cancer | 245 mg | 1.9 | 12.4 | 4.7% | -31% | ND | -88% | - | None |
| Cholangiocarcinoma | 130 mg | 1.9 | 5.1 | 11.0% | -39% | -59% | -100% | - | H1047R |
| Breast cancer  | 100 mg | 3.6 | 5.6 | -20.0% | -41% | 0% | -87% | - | PTEN decreased |
| Ovarian cancer  | 100 mg | 4.5 | 9.2 | 4.3% | -13% | -56% | -90% | -86% | PTEN negative; high PIK3CA polysomy |